[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Institut d'Investigació Biomèdica de Bellvitge\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":239},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,48,86,129,163,185,211],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100635673","phase-4-efficacy-and-safety-of-daridorexant-in-patients-with-major-depressive-disorder-and-insomnia-100635673",false,"NCT07555743","Efficacy and Safety of Daridorexant in Patients With Major Depressive Disorder and Insomnia","Efficacy and Safety of Daridorexant in Patients With Major Depressive Disorder (MDD) and Insomnia: Double-blind, Randomized, Controlled Trial","Inclusion Criteria:\n\n* Age Range: 18-99 years old.\n* Patients with a current major depressive episode according to DSM-5, in a stable phase (defined as at least 4 weeks without significant changes in antidepressant treatment and no psychiatric hospitalizations in the previous 8 weeks) and with moderate or greater severity, as indicated by a total score of\n\n  * 20 on the Montgomery-Åsberg Depression Rating Scale (MADRS).\n* Insomnia disorder confirmed according to DSM-5\n\n  * Insomnia Severity: Insomnia Severity Index (ISI) score = o \\>15.\n  * Medication Stability defined by :\n\n    * Stable doses of antidepressants, mood stabilizers, or antipsychotics for at least 1 month prior to baseline (T0).\n    * Melatonin, Benzodiacepines, sedative antidepressants or sedative antipsychotics use for insomnia should follow a wash out protocol described below.\n* Informed Consent: Ability and willingness to provide written informed consent.\n* Acceptance of Protocol Requirements: Agreement to adhere to all scheduled visits, treatment plans, and study procedures.\n\nExclusion Criteria:\n\n* Other Current Psychiatric Disorders: Any current psychiatric disorder other than major depressive disorder (e.g., active psychotic disorders, mania, hypomania, acute schizophrenia, schizoaffective disorder).\n* Use of Non-Permitted Sleep Medications: Concurrent use of melatonin, benzodiazepines, sedative antidepressants or sedative antipsychotics use for insomnia not allowed by the protocol and unwillingness to follow the slow- taper schedule constitutes an exclusion criterion.\n* No concurrent sleep medications at least 30 days prior to baseline. Exclusion criteria if the patient has withdrawal symptoms and\u002For sleep disturbances measured by BWSQ prior to baseline.\n* Uncontrolled Severe Medical Conditions: Any condition that could interfere with study procedures, safety, or outcome measures (e.g., unstable cardiovascular, respiratory, neurological, or endocrine disorders).\n* Pregnancy or breastfeeding\n* Cognitive Impairments: Significant impairments that prevent the comprehension or completion of study questionnaires or procedures.\n* Hypersensitivity: Known allergy or hypersensitivity to daridorexant or any of its excipients.\n* Specific Sleep Disorders: Sleep apnea or hypopnea index ≥ 15 events\u002Fhour (based on American Academy of Sleep Medicine criteria) or any event associated with oxygen saturation \\\u003C 80% (as measured by polysomnography).\n* Periodic limb movement index ≥ 15 events\u002Fhour (as measured by polysomnography). Restless legs syndrome, circadian rhythm sleep-wake disorders, REM behavior disorder, or narcolepsy.\n* Concomitant Use with Moderate and potent CYP3A4 Inhibitors: Prohibited due to potential drug interaction (refer to protocol section 4.5 for specifics).\n* Moderate and severe hepatic Impairment: Any hepatic condition deemed unsafe for daridorexant use.\n* Relapse or Worsening of the Main Diagnosis: Relapse of depression whose severity precludes continued participation according to the investigator's judgment.\n* Substance Use Disorder: History of substance use disorder without sustained remission. Exception: past sedative abuse may be permissible if remission criteria are clearly met, as determined by the investigator.\n* Excessive Caffeine Intake: Daily consumption of \\>400 mg of caffeine (e.g., \\>4 standard cups of coffee).\n* High-Risk Alcohol Consumption: Alcohol intake above recommended risk thresholds in accordance with the guidelines of the Spanish Ministry of Health: i.e., \\>4 standard drinks\u002Fday (\\>40g\u002Fd) for men, \\>2 standard drinks\u002Fday (\\>20g\u002Fd) for women.","ALL","18 Years","99 Years",{"count":20,"type":21},134,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this clinical trial is to evaluate the efficacy and safety of Daridorexant in major depressive disorder (MDD) patients with comorbid insomnia. The main questions to answer are:\n\n1. Does Daridorexant improve the severity of insomnia as measured by the Insomnia Severity Index (ISI)?\n2. Does Daridorexant have an impact on depressive symptoms?\n\nIn order to address these questions, researchers will compare Daridorexant with a placebo to evaluate its impact on both insomnia and MDD-related symptoms.\n\nParticipants will:\n\n* Receive Daridorexant or placebo for a duration of three months\n* Complete a Sleep Diary and other questionnaires assessing sleep and depressive symptoms.\n* Undergo polysomnography to obtain objective measurements of sleep parameters.",[27,28],"Insomnia","Major Depressive Disorder",[30,31,27,32,33,34],"Daridorexant","Clinical Trial","Major depressive disorder","Polysomnography","Insomnia Severity Index","NOT_YET_RECRUITING","2026-04-21",{"date":38,"type":39},"2026-04-29","ACTUAL",{"date":41,"type":21},"2026-04",{"date":43,"type":21},"2028-10",{"name":45,"class":46},"Institut d'Investigació Biomèdica de Bellvitge","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":47},"100616295","phase-2-study-assessing-reduced-hpv-infectivity-and-transmission-in-hpv-positive-women-following-vaccination-with-9vhpv-100616295","NCT07303751","Study Assessing Reduced HPV Infectivity and Transmission in HPV-Positive Women Following Vaccination With 9vHPV","HPV Vaccination and Infectivity Reduction in HPV-positive Women","RIFT-SSA","Inclusion Criteria:\n\n* Born female\n* Aged between 18-29 years old;\n* Living in Kambia district (or neighbouring district if included) without plans to move away in the next 12 months;\n* Willing to participate in the study and have signed the informed consent form;\n* In good health as determined by a medical history (a physical examination will be conducted if necessary according to the clinician's judgement);\n* Willing to be tested for HIV;\n* Are HIV negative at the screening visit;\n* Not pregnant;\n* Able to pass a Test of Understanding (TOU);\n* Willing to provide cervical, urine and blood samples;\n* Agree to be vaccinated with a single dose of Gardasil9® if randomised to the vaccine arm at Day 0;\n* Have no visible suspicious cervical lesions on examination.\n* Agree to a pregnancy test at screening and before any HPV vaccination.\n\nExclusion Criteria:\n\n* They have been previously vaccinated against HPV;\n* They have a chronic condition, such as autoimmune conditions, degenerative diseases, neurologic or genetic diseases among others;\n* They are HIV positive or immunocompromised;\n* They are pregnant or planning to get pregnant in the next 12 months;\n* They are less than three months post-partum or currently breastfeeding;\n* They are allergic to one of the vaccine components or to latex;\n* They are sexually active and are not using, or are not willing to use, an effective birth control method from D-14 until 60 days after the last vaccine dose\n* The nurse or clinician determining the eligibility, in agreement with principal investigator, considers that there is a reason that precludes participation.","FEMALE","29 Years",{"count":59,"type":21},80,[61],"PHASE2","This is a randomized, open-label trial, to assess whether a single dose of HPV nonavalent vaccine, administered to HIV uninfected, unvaccinated women with high risk HPV16\u002F18\u002F31\u002F33\u002F45\u002F52 or 58 can decrease the infectivity of shed HPV viruses.\n\nOur hypothesis is that vaccination will have little or no impact on HPV sample positivity by DNA PCR since the viral particles will continue to be produced and released, but that particles will be neutralized by vaccine-induced antibodies, thereby reducing their infective capacity. Cervical samples will be collected at randomisation and at 6 months, to compare infectivity of shed HPV viruses.",[64,65,66],"HPV","High-risk HPV (Any Strain)","Human Papillomavirus (HPV) Infections",[68,69,70,66,71,72,73,74,75,76,77],"Cervical cancer","Cervical Intraepithelial Neoplasia Grade I\u002F II\u002F III (CIN I\u002FII\u002FIII)","Squamous Intraepithelial Lesions of the Cervix, High\u002F Low Grade","High-risk HPV","HPV-16\u002F 18","HPV DNA Tests","HPV Vaccines","HPV Nonavalent Vaccine","Gardasil-9","9vHPV","2026-02-09",{"date":80,"type":39},"2026-02-11",{"date":82,"type":21},"2026-02-01",{"date":84,"type":21},"2027-02-01",{"name":45,"class":46},{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":98,"conditions":99,"keywords":104,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":47},"100597416","weight-management-in-obese-cancer-patients-during-curative-active-treatment-100597416","NCT07058207","Weight Management in Obese Cancer Patients During Curative Active Treatment","Weight Management in Obese Cancer Patients During Curative Active Treatment (CANOBESE Study): A Feasibility Study","CANOBESE","Inclusion Criteria:\n\n* Adult (age 18+) with pathologically confirmed malignant solid tumors, stage II-IV, elected for oncological treatment (chemo, radio, or both) with curative intend.\n* Expected oncological treatment time ≥ 3 months.\n* BMI ≥ 30 kg\u002Fm²\n* Resident in the Barcelona area up to the completion of cancer treatment.\n* ECOG Perfomance Status (PS) 0-1\n* Availability of internet access.\n\nExclusion Criteria:\n\n* Patients with melanoma and brain tumours.\n* Surgery as the only treatment.\n* Tumour localizations with high risk of malnutrition (such as head and neck, upper gastrointestinal tract, or pancreatic cancer):\n* Pregnancy or breastfeeding\n* Another active malignancy\n* Current health or medical condition that affects weight status, e.g., untreated hyper- or hypothyroidism,etc\n* Pre-existing medical condition that precludes adherence to unsupervised exercise, e.g., severe orthopedic conditions, scheduled for a hip or knee replacement, bone metastases, paralysis, dementia, untreated stage 3 hypertension, or unstable angina, heart attack, congestive heart failure or conditions that dictated hospitalization or oxygen within 6-months.\n* Unable to read or understand Spanish or Catalan\n* Enrolled in a weight loss program\n* Active suicidal ideation, anorexia, bulimia, binge eating disorder, current substance abuse or dependence (besides nicotine dependence)\n* Use of pacemaker or another electrical implanted device\n* History of bariatric (or LapBand) surgery, or considering or currently on a wait-list for bariatric or LapBand surgery\n* Patients with any concurrent medical or psychological condition that, in the investigator's opinion, would jeopardize the safety of the patient or compliance with the protocol.",{"count":95,"type":21},50,[97],"NA","This is a feasibility study intervention to fifty cancer patients with obesity and with newly diagnosed stage II-IV solid tumors undergoing curative treatment recruited at the Catalan Institute of Oncology (ICO) in L'Hospitalet, Spain.\n\nThe investigators hypothesize that weight management during cancer treatment could enhance health outcomes for this population. The feasibility of a multimodal weight loss management program will be assesses, including a personalized hypocaloric and high-protein diet combined with a supervised exercise home-program and behavioural support.",[100,101,102,103],"Obesity","Solid Neoplasm","Stage II-IV","Curative Treatment",[100,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119],"Neoplasms","Antineoplasic agents","Chemotherapy","Radiotherapy","Weight Loss","Physical Activity","Feasibility Studies","Patient Compliance","Patient Motivation","Patient Adherence","Patient Dropouts","Treatment-related adverse effects","Biomarkers","nutritional intervention","curative-intent treatment","RECRUITING","2025-07-24",{"date":123,"type":39},"2025-07-28",{"date":125,"type":39},"2025-07-22",{"date":127,"type":21},"2027-03",{"name":45,"class":46},{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":140,"conditions":141,"keywords":147,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":47},"100595885","patient-centered-personalized-cardiac-rehabilitation-in-post-acute-coronary-syndrome-break-trial-100595885","NCT07038265","Patient-centered Personalized Cardiac Rehabilitation in Post Acute Coronary Syndrome (BREAK-trial)","Patient-centered Cardiac rehaBilitation pRogramE in Post Acute Coronary Syndrome:Identification of Key Barriers and Evaluation of Personalized Intervention (BREAK-trial)","BREAK","Inclusion Criteria:\n\n1. Patient aged ≥ 18 years\n2. Patients discharged within the last 30 days after an admission for ACS or in the discharge planning process for an admission for ACS.\n3. The patient is able to fully communicate with the research team and comply with all study procedures.\n4. The patient voluntarily signs and dates the informed consent form approved by the ethics committee\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years\n2. Participation in another clinical trial\n3. Moderate or severe cognitive impairment in the absence of a competent caregiver\n4. Absence of social support\n5. Institutionalized patient\n6. Life expectancy \\\u003C1 year\n7. Candidates for end-of-life care\n8. Severe psychiatric illness\n9. Planned cardiac surgery including transplant or circulatory support implant\n10. Death before hospital discharge in patients included in the hospital discharge planning phase\n11. Carrier of heart transplant.\n12. Patient unable or refusing to give written informed consent to participate\n13. Patients who, in the opinion of the investigator, are unsuitable candidates for the study",{"count":138,"type":21},202,[97],"The primary objective of this study is to compare an integrated, multidisciplinar patient-centered CRP (Cardiac Rehabilitation Program) (intervention group) especially focused on covering the needs for the female and fragile population to the usual care conventional CRP (control group)",[142,143,144,145,146],"Acute Coronary Syndromes (ACS)","Cardiac Rehabilitation","Frailty","Women","Women's Health",[148,149,150,151,152,153,154],"frailty","sarcopenia","cardiac rehabilitation","gender perspective","acute coronary syndrome","coronary artery disease","patient-centered care","2025-06-17",{"date":157,"type":39},"2025-06-26",{"date":159,"type":39},"2025-05-26",{"date":161,"type":21},"2027-11",{"name":45,"class":46},{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":22,"phases":172,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":181,"leadSponsor":183,"locationsCount":184},"100552571","left-septal-or-deep-septal-pacing-to-prevent-pacing-induced-cardiomyopathy-100552571","NCT06474819","Left Septal or Deep Septal Pacing to Prevent Pacing-induced Cardiomyopathy","DEEP","Inclusion Criteria:\n\n* First implant of a single-chamber or dual chamber pacemaker due to persistent bradycardia associated with high degree atrio-ventricular (AV) block (complete AV block or second degree type II AV block), with second-degree type I AV block (symptomatic or associated with intra-hisian or infra-hisian block), or with atrial fibrillation with symptomatic slow ventricular rate (\\\u003C45lpm).\n* LVEF\\>50% at echocardiography performed maximum 7 days before pacemaker implant.\n* Informed consent signature.\n\nExclusion Criteria:\n\n* Life expectancy \\\u003C12 months\n* Severe cardiac valvular abnormality requiring intervention\n* Unstable Angina, Acute myocardial infarction, coronary revascularization, valvular surgery or valvular percutaneous intervention in the 90 days prior to pacemaker implant.\n* Inclusion in another trial which may influence the results of this study.",{"count":171,"type":21},326,[97],"Multicenter randomized controlled trial which will include patients with left ventricular ejection fraction \\>50% requiring a first implant of a cardiac pacemaker with expected high pacing percentages.\n\nPatients will be randomized 1:1 to right ventricular apical pacing vs left septal or deep septal pacing. The primary endpoint will be pacing-induced cardiomyopathy during the first year of follow-up.",[175,176],"Complete Heart Block","Second Degree Atrioventricular Block Möbitz Type II","2024-07-12",{"date":179,"type":39},"2024-07-15",{"date":177,"type":39},{"date":182,"type":21},"2027-01-12",{"name":45,"class":46},6,{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":22,"phases":195,"briefSummary":196,"conditions":197,"keywords":201,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":47},"100553057","reversibility-of-cardiac-conduction-disturbances-following-tavi-100553057","NCT06481137","Reversibility of Cardiac Conduction Disturbances Following TAVI","InvesTigAtion of the reVersIbility of caRdiac Conduction disturbancEs Following Percutaneous Aortic ValvE Implantation in Patients With Severe aoRtic StEnosis: The TAVI-REVERSE Study","TAVI-REVERSE","Inclusion Criteria:\n\n* Patients with indication for electrophysiological (EP) study after TAVI implantation according to European Guidelines. Patients must have persistent electrocardiographic conduction disturbances (ECG-CDs) that are present from day 2 after TAVI implantation (≥ 48h post-procedure):\n* De novo LBBB with QRS complex \\>150ms and\u002For PR interval ≥240ms.\n* QRS widening or post-procedural PR lengthening \\> 20ms in patients with baseline ECG-CDs.\n\nExclusion Criteria:\n\n* Patients with previous pacemaker or implantable defibrillator.\n* Patients with baseline complete right bundle branch block.\n* Patients in need of cardiac resynchronization or physiological stimulation following TAVI.\n* Valve-in-valve procedures.\n* TAVI procedures in patients with severe aortic insufficiency.\n* Inability to sign the informed consent form.",{"count":194,"type":21},209,[97],"The management of patients with conduction disturbances (CDs) after transcatheter aortic valve implantation (TAVI) is unclear, especially in those with de novo electrocardiographic CDs (ECG-CDs) such as left bundle branch block.\n\nIn this study, the investigators will evaluate the incidence of retrogradation of infra-Hisian CDs in patients with de novo ECG-CDs and positive electrophysiological study (EPS) 3-7 days following TAVI. In addition, the investigators will evaluate the need for cardiac pacing and the incidence of clinical events in patients with negative EPS performed 3-7 days following TAVI.\n\nIn this multicenter, longitudinal, prospective study, patients with clinical indication of EP study due to new-onset ECG-CDs after TAVI will be included. A permanent pacemaker will be implanted in patients with positive EPS and a second EPS will be performed in 30-45 days. Additionally, these patients will undergo 4-week continuous monitoring using the ePatch (Philips) long-term Holter recorder, to identify episodes of paroxysmal complete atrioventricular block. Patients with negative EP study will undergo clinical follow-up and continuous monitoring for 4 weeks.",[198,199,200],"Aortic Stenosis","Transcatheter Aortic Valve Implantation","Conduction Disturbances",[202,199,200],"Aortic stenosis","2024-06-25",{"date":205,"type":39},"2024-07-01",{"date":207,"type":39},"2024-06-17",{"date":209,"type":21},"2026-12-31",{"name":45,"class":46},{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":16,"minAge":219,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":22,"phases":222,"briefSummary":223,"conditions":224,"keywords":226,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":238},"100504997","cardioinhibitory-reflex-syncope-permanent-pacemaker-therapy-or-cardioneuroablation-100504997","NCT05855603","Cardioinhibitory Reflex Syncope. Permanent Pacemaker Therapy or Cardioneuroablation?","Recurrent Cardioinhibitory Reflex Syncope. PermANent PAcemaker Therapy or CardionEuroablation? A Multicenter RAndomized Clinical Trial","PANACEA","Inclusion Criteria:\n\n* Aged more than 40 years.\n* Having a 12-month history that includes at least two documented episodes of spontaneous reflex syncope or one episode that led to injury in addition to at least two presyncopal events, refractory to all recommended types of standard treatment.\n* Bradycardia-syncope correlation (at least 3 seconds of asystole due to sinus arrest or atrio-ventricular block) confirmed by ECG during spontaneous syncope.\n* If lacking ECG evidence during spontaneous syncope, a cardioinhibitory response (VASIS type 2A or 2B) on tilt test.\n* Displaying indicators for pacing such as those suggested in the ESC guidelines for a class I recommendation for patients with reflex syncope.\n* Significantly decreased quality of life due to syncope.\n* Sinus rhythm on ECGs.\n* Obtained written informed consent.\n\nExclusion Criteria:\n\n* Intrinsic sinus or atrioventricular nodal disease with a proven indication for permanent pacemaker implantation.\n* Evidence of structural heart disease.\n* Contraindications to ablation in the right or left atrium.\n* Life expectancy \\\u003C12 months.\n* Lacking willingness to comply with the randomization procedure.","40 Years",{"count":221,"type":21},90,[97],"Reflex syncope is the most common form of syncope. It can lead to injuries and affect quality of life. Nonpharmacological and medical therapies have limited effectiveness. In certain patients, cardiac pacing seem to be beneficial. More recently cardioneuroablation (CNA) has emerged as a novel therapy for reflex syncope. The investigators aim to determine whether CNA is more effective than cardiac pacing at reducing the rate of cardioinhibitory-type reflex syncope.",[225],"Reflex Syncope",[227,228,229],"Cardioneuroablation","Permanent cardiac pacing","Vasovagal syncope","2024-01-22",{"date":232,"type":39},"2024-01-25",{"date":234,"type":39},"2023-11-22",{"date":236,"type":21},"2027-02-22",{"name":45,"class":46},10,""]